CeriBell
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions direc...
Latest News
13 days ago · zacks.com
CeriBell, Inc. (CBLL) Reports Q3 Loss, Tops Revenue EstimatesCeriBell, Inc. (CBLL) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.37 per share a year ago.
13 days ago · seekingalpha.com
CeriBell, Inc. (CBLL) Q3 2026 Earnings Call TranscriptCeriBell, Inc. (CBLL) Q3 2026 Earnings Call Transcript
13 days ago · zacks.com
Compared to Estimates, CeriBell, Inc. (CBLL) Q3 Earnings: A Look at Key MetricsThe headline numbers for CeriBell, Inc. (CBLL) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
13 days ago · marketbeat.com
CeriBell Q3 Earnings Call HighlightsCeriBell NASDAQ: CBLL reported third-quarter revenue growth of approximately 30% as the company added a record number of hospital accounts and increased usage of its seizure-monitoring platform among existing customers. Management also outlined plans to commercially launch its Delirium Monitoring Solution and introduce its next-generation Omni hardware platform in 2027.
13 days ago · globenewswire.com
Ceribell Reports Third Quarter 2026 Financial ResultsSUNNYVALE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the third quarter ended September 30, 2026.
15 days ago · globenewswire.com
Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring SolutionSUNNYVALE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ceribell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the commercial launch of its delirium monitoring solution on its point-of-care brain monitoring platform.
19 days ago · globenewswire.com
Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumSUNNYVALE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York City. The fireside chat will take place on Wednesday, November 11, 2026, at 7:00 a.m. Pacific Standard Time / 10:00 a.m. Eastern Standard Time.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove CBLL